Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.
about
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancerThe performance of NLST screening criteria in Asian lung cancer patientsLiquid biopsy genotyping in lung cancer: ready for clinical utility?Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient PlasmaCorrelation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancerComparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation statusEGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients.Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-AnalysisEpidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern ChinaReal-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study
P2860
Q26775376-0339F088-739B-4CF4-BD33-72A947D0594FQ28082499-D3862CEA-CE01-4F44-A711-BAAAD37A1947Q28394235-6F53C6F9-B608-4C28-AFE5-4029044CB521Q33567037-844CF622-1C9F-4129-9CE5-94A804D3A92BQ33598423-A44B5344-13A6-4A8D-B682-1C42A5DA7DEFQ33703063-204255C7-EA72-4C03-BB32-38032CEAAB48Q36270116-91A023EF-E599-4FE7-860A-352D81A5A23BQ36375343-9373E280-C9BE-428D-946E-76E2C49CAA0FQ36844366-86439A4A-D969-49D9-95BE-55BF92DAEB91Q37536958-B876A02C-5D0B-4452-B03D-A34C1931C229Q37592893-8C4F814F-0BDC-41EC-9705-5E50E519F5F1Q37693426-B839E91A-862D-4F65-8667-10EA77F2928DQ37701499-ABBC867A-7A46-409C-AC33-8F5893FD1B90Q38694431-ED779057-6603-48D6-B787-1EE858D57070Q38859701-7ED2D2C9-E163-4ACF-AB53-AA4EA0A81109Q41260159-2F646B74-93F8-40E2-B686-D7B5661CD367Q41866575-037360BB-78F4-458B-B07F-824C56C5AA0AQ41895086-DBFC959B-C0B4-4D8C-BEFF-121C54E816F3Q43172646-DCF4A6D9-E908-4800-AB47-0BAD64FCB72DQ47563363-8EFA9DAD-D65D-4021-B59A-216DCAE77209Q49379624-A0446166-3D79-451E-88B8-3AA8DED979A1Q57147737-9A902B3E-6926-44BB-B190-7D132DFF28ABQ58603542-47C089A6-6EE8-4B38-859E-8E4515A49CA5Q59137536-1583FF45-9706-451B-895D-B88DAD21F2EA
P2860
Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Peripheral blood for epidermal ...... all cell lung cancer patients.
@ast
Peripheral blood for epidermal ...... all cell lung cancer patients.
@en
Peripheral blood for epidermal ...... all cell lung cancer patients.
@nl
type
label
Peripheral blood for epidermal ...... all cell lung cancer patients.
@ast
Peripheral blood for epidermal ...... all cell lung cancer patients.
@en
Peripheral blood for epidermal ...... all cell lung cancer patients.
@nl
prefLabel
Peripheral blood for epidermal ...... all cell lung cancer patients.
@ast
Peripheral blood for epidermal ...... all cell lung cancer patients.
@en
Peripheral blood for epidermal ...... all cell lung cancer patients.
@nl
P2093
P2860
P1476
Peripheral blood for epidermal ...... all cell lung cancer patients.
@en
P2093
Caicun Zhou
Chunxia Su
Mingchuan Zhao
Ningning Cheng
Ruixin Ren
Shengxiang Ren
Weijing Cai
P2860
P304
P356
10.1016/J.TRANON.2014.04.006
P577
2014-06-17T00:00:00Z